Latest Content

Rising oncology costs and fragmented data compromise care. Payers must adopt a blueprint integrating clinical intelligence, next-generation utilization management, and partnerships to achieve measurable value.

Carl Regillo, MD, on missed wet AMD injections, treatment switching, and how gene therapy could ease chronic burden.

Quest Diagnostics is integrating its Haystack MRD and genomic profiling tests into Flatiron's OncoEMR, starting with an AON community oncology pilot.

INCA033989 demonstrated spleen reductions, anemia responses, and molecular improvements in patients with mutant calreticulin–positive myelofibrosis.

Vera's atacicept (Trutakna) wins FDA accelerated approval after a 46% proteinuria drop in the ORIGIN 3 trial.

A UK Biobank analysis found that IL-6, but not hsCRP, modified the association between elevated lipoprotein(a) and coronary artery disease risk.

The AGAVE-201 analysis found no significant bone health concerns with axatilimab in chronic GVHD, showing stable biomarkers and no increased fractures.

Bhavana Bhatnagar, DO, who moved from academic to community oncology, shares why stronger academic-community partnerships are essential for patient care

A retrospective cohort study found stable blood pressure alongside significant reductions in LVOT gradients, regardless of hypertension status.